Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology

The Biology of MPNs: Subtypes and Genetic Drivers

At a Glance

Myeloproliferative neoplasms (MPNs) are driven by genetic mutations—most commonly JAK2, CALR, or MPL—that cause the bone marrow to overproduce blood cells. Identifying your specific subtype (PV, ET, or PMF) and mutation helps doctors tailor the best monitoring and treatment plan for you.

To understand myeloproliferative neoplasms (MPNs), it helps to think of your bone marrow as a construction site. In a healthy body, the foreman (your genetics) sends precise signals to start or stop building blood cells. In an MPN, a genetic “glitch” or mutation causes the foreman to leave the power switch stuck in the “on” position, leading to a constant overproduction of cells [1][2].

The Power Switch: The JAK-STAT Pathway

The primary biological engine behind MPNs is the JAK-STAT pathway [3]. This is a signaling route inside your cells that tells them to grow and divide. In most patients, one of three “driver mutations” is responsible for keeping this pathway active:

  • JAK2 (Janus Kinase 2): Found in nearly 95% of Polycythemia Vera (PV) cases and about 50-60% of ET and PMF cases [4][5]. It acts like a broken switch that can’t be turned off.
  • CALR (Calreticulin): Found in about 20-30% of ET and PMF cases [4]. This protein normally helps fold other proteins, but when mutated, it incorrectly activates the growth signal [6][7].
  • MPL (Myeloproliferative Leukemia Virus Oncogene): Found in about 3-5% of ET and PMF cases [4]. It directly affects the receptor that tells the body to make platelets.

Approximately 10-15% of patients with ET or PMF are triple-negative, meaning none of these three mutations are found [8][9]. In these cases, doctors often use advanced testing like Next-Generation Sequencing (NGS) to look for rarer “passenger” mutations that might be driving the disease [10][11].

Comparing the Three Subtypes

While they share the same biological “engine,” MPNs are named based on which “product” the factory is over-making:

Subtype Primary Overproduction Key Driver Mutation
Polycythemia Vera (PV) Red Blood Cells JAK2 (>95%) [5]
Essential Thrombocythemia (ET) Platelets JAK2, CALR, or MPL [4]
Primary Myelofibrosis (PMF) Fibrous (scar) tissue JAK2, CALR, or MPL [4]

The “True ET” vs. “Pre-fibrotic PMF” Distinction

One of the most important steps in a modern diagnosis is distinguishing between True ET and Pre-fibrotic PMF (Pre-PMF).

To the naked eye or a standard blood test, these two conditions can look identical because both cause high platelet counts [12]. However, a specialist looking at a bone marrow biopsy can see the difference:

  • True ET: The marrow shows an increase in large, mature-looking megakaryocytes (platelet-making cells) but no signs of scarring [13].
  • Pre-PMF: The marrow shows “atypical” or abnormally clustered cells and very early signs of fibrosis (scarring) [13][14].

Why it matters: Distinguishing between them is vital because Pre-PMF may carry a higher risk of progressing to more advanced stages and may require more frequent monitoring or different treatment strategies compared to True ET [15][16][17]. Identifying Pre-PMF early allows your care team to be more proactive in your management [18][19].

Back to Home Page

Common questions in this guide

What are the main subtypes of MPNs?
The three main subtypes are Polycythemia Vera (PV) which overproduces red blood cells, Essential Thrombocythemia (ET) which overproduces platelets, and Primary Myelofibrosis (PMF) which causes fibrous scarring in the bone marrow.
What is a driver mutation in an MPN?
A driver mutation is a genetic change, such as JAK2, CALR, or MPL, that acts like a broken switch in your bone marrow cells. It causes the JAK-STAT pathway to stay turned on, continuously telling your body to overproduce blood cells.
What does it mean to be triple-negative?
Being triple-negative means you do not have the three most common MPN mutations (JAK2, CALR, or MPL). If you are triple-negative, your specialist may use Next-Generation Sequencing (NGS) to look for rarer passenger mutations driving your condition.
Why is it important to tell the difference between True ET and Pre-fibrotic PMF?
True ET and Pre-PMF can look identical on standard blood tests because both cause high platelet counts. However, Pre-PMF carries a higher risk of progressing to advanced stages. A bone marrow biopsy is required to look for early signs of scarring and make an accurate diagnosis.
What is the JAK-STAT pathway?
The JAK-STAT pathway is a communication route inside your cells that controls cell growth and division. In MPNs, genetic glitches cause this pathway to become overactive, acting as the primary biological engine that drives the continuous overproduction of blood cells.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific driver mutation was found in my tests (JAK2, CALR, or MPL), and what is my 'allele burden' (the percentage of mutated cells)?
  2. 2.My biopsy report says I have ET—can you confirm if it was specifically checked for the features of 'pre-fibrotic myelofibrosis'?
  3. 3.If I am 'triple-negative,' what additional tests or NGS (Next-Generation Sequencing) panels should we run to understand my risk?
  4. 4.How does my mutation type specifically change my risk for blood clots versus my risk for disease progression?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.

    Patterson-Fortin J, Moliterno AR

    Current hematologic malignancy reports 2017; (12(5)):424-431 doi:10.1007/s11899-017-0411-0.

    PMID: 28948454
  2. 2

    The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia.

    Moser B, Edtmayer S, Witalisz-Siepracka A, Stoiber D

    Biomedicines 2021; (9(8)) doi:10.3390/biomedicines9081051.

    PMID: 34440253
  3. 3

    Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.

    Durham GA, Williams JJL, Nasim MT, Palmer TM

    Trends in pharmacological sciences 2019; (40(5)):298-308 doi:10.1016/j.tips.2019.03.001.

    PMID: 30948191
  4. 4

    Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.

    Vu HA, Thao TT, Dong CV, et al.

    Asian Pacific journal of cancer prevention : APJCP 2019; (20(9)):2775-2780 doi:10.31557/APJCP.2019.20.9.2775.

    PMID: 31554376
  5. 5

    Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.

    Abdelghani M, Hammami H, Zidi W, et al.

    Journal of clinical laboratory analysis 2022; (36(8)):e24522 doi:10.1002/jcla.24522.

    PMID: 35754115
  6. 6

    Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.

    Shide K, Kameda T, Yamaji T, et al.

    Leukemia 2017; (31(5)):1136-1144 doi:10.1038/leu.2016.308.

    PMID: 27807369
  7. 7

    Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.

    Pasca S, Chifotides HT, Verstovsek S, Bose P

    International review of cell and molecular biology 2022; (366()):83-124 doi:10.1016/bs.ircmb.2021.02.008.

    PMID: 35153007
  8. 8

    CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.

    Ojeda MJ, Bragós IM, Calvo KL, et al.

    Hematology (Amsterdam, Netherlands) 2018; (23(4)):208-211 doi:10.1080/10245332.2017.1385891.

    PMID: 28990497
  9. 9

    Long term follow-up after liver transplantation from a JAK2 mutation positive donor.

    Lazo-Langner A, Ainsworth P, McAlister V

    Hepatobiliary surgery and nutrition 2019; (8(2)):189-191 doi:10.21037/hbsn.2019.01.06.

    PMID: 31098378
  10. 10

    A case report of donor cell-derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation.

    Mroczkowska-Bękarciak A, Wróbel T

    Oncotarget 2025; (16()):44-50 doi:10.18632/oncotarget.28686.

    PMID: 39907609
  11. 11

    Lab tests for MPN.

    Moncada A, Pancrazzi A

    International review of cell and molecular biology 2022; (366()):187-220 doi:10.1016/bs.ircmb.2021.02.010.

    PMID: 35153004
  12. 12

    How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024.

    Griesshammer M, Al-Ali HK, Eckardt JN, et al.

    Annals of hematology 2025; (104(1)):295-306 doi:10.1007/s00277-025-06191-7.

    PMID: 39888352
  13. 13

    Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

    Rumi E, Cazzola M

    Blood 2017; (129(6)):680-692 doi:10.1182/blood-2016-10-695957.

    PMID: 28028026
  14. 14

    Diagnosis and management of prefibrotic myelofibrosis.

    Rumi E, Sant'Antonio E, Boveri E, et al.

    Expert review of hematology 2018; (11(7)):537-545 doi:10.1080/17474086.2018.1484280.

    PMID: 29862872
  15. 15

    Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.

    Misawa K, Yasuda H, Araki M, et al.

    International journal of hematology 2018; (107(6)):673-680 doi:10.1007/s12185-018-2421-7.

    PMID: 29464483
  16. 16

    SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis.

    Vachhani P, Loghavi S, Bose P

    Clinical lymphoma, myeloma & leukemia 2024; (24(7)):413-426 doi:10.1016/j.clml.2024.01.009.

    PMID: 38341324
  17. 17

    The new WHO classification for essential thrombocythemia calls for revision of available evidences.

    Barbui T, Thiele J, Ferrari A, et al.

    Blood cancer journal 2020; (10(2)):22 doi:10.1038/s41408-020-0290-9.

    PMID: 32098949
  18. 18

    Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia.

    Lekovic D, Bogdanovic A, Sobas M, et al.

    Cancers 2023; (15(16)) doi:10.3390/cancers15164180.

    PMID: 37627208
  19. 19

    Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.

    Kuo MC, Chuang WY, Chang H, et al.

    American journal of clinical pathology 2023; (159(5)):474-483 doi:10.1093/ajcp/aqac173.

    PMID: 36857745

This page explains the basic biology and genetics of MPNs for educational purposes. Always consult your hematologist to interpret your specific genetic mutations, biopsy results, and treatment plan.

Get notified when new evidence is published on Myeloproliferative neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.